SOURCE: AtheroNova Inc.

AtheroNova Inc.

January 10, 2011 08:45 ET

AtheroNova Files Patent Application for Potentially Revolutionary Obesity Treatment

IRVINE, CA--(Marketwire - January 10, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced the filing of a patent application for the use of the Company's delipidization technology in the treatment of obesity. These filings address biocompatible compounds (for example, bile acids and terpenes), made available to the systemic circulation in an effective amount to treat obesity.

"Obesity has become one of the largest health problems in modern human history. With recognized co-morbidities ranging from stroke, atherosclerosis, heart disease and diabetes to erectile dysfunction, the obesity epidemic has been growing virtually unchecked," said Thomas W. Gardner, CEO of AtheroNova. "During the research and development of our delipidization technology for the prevention and regression of atherosclerotic plaques, we observed that some of the same attributes of our technology that enable the prevention and regression of fatty plaque deposits in arteries may also play a role in the regression of fat deposits both locally and systemically. As a result, we have filed an application with the United States Patent and Trademark Office for the use of this technology in the treatment of obesity."

"The statistics indicating the increasing prevalence of obesity are overwhelming. Many studies have indicated that the United States and industrialized nations across the globe are in the grip of an obesity epidemic that has been growing at a shocking rate. According to the Centers for Disease Control and Prevention (CDC), over 27% of the adult population in the United States was obese in 2009, up by over 33% from 20% in 2000. Over the past decade, obesity has become recognized as a national health threat and a major public health challenge. In 2007-2008, approximately 72.5 million adults in the United States were obese. From 1987 to 2001, diseases associated with obesity accounted for 27% of the increases in U.S. medical costs. For 2006, medical costs associated with obesity were estimated at as much as $147 billion, and obese persons had estimated medical costs that were $1,430 higher than persons of normal weight. Clearly, there is a huge unmet need that we seek to address. As we continue our research and development, we have an interest in developing clinical trials to study the safety and efficacy of our plaque regression technology, as well as our anti-obesity technology," stated Mr. Gardner.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its technologies, to be used in pharmaceutical-grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the research and development of the company's technology and the suitability of its compounds for certain. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the results of decisions by the USPTO and the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company contact:

    Thomas Gardner
    Chief Executive Officer
    (949) 476-1100

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:

    Leon Hamerling
    Investor Media Group
    (877) 725-2500